Lifera Omics Appoints Chief Medical & Genomics Officer

Lifera Omics, a subsidiary of Lifera that was launched in January 2024, has appointed human geneticist, Prof. Fowzan Sami Alkuraya, as its Chief Medical and Genomics Officer, who will also be added to the Board of Lifera Omics.
 
Alkuraya’s experience in human genomics built over 17 years will contribute significantly to enabling Lifera Omics’ objectives.
 
Alkuraya, a former Chairman of Translational Genomics at King Faisal Specialist Hospital and Research Center in Riyadh and current Professor of Human Genetics at Alfaisal University, has significantly contributed to the field of genomics, through over 590 scientific publications in prestigious international journals and as a frequent speaker at international scientific conferences on genomic medicine and precision health.
 
Alkuraya has garnered numerous prestigious awards, including the William King Wilson Prize in Genetics from Harvard Medical School, the King Salman Award for Disability Research, and the Curt Stern Award from the American Society of Human Genetics – the first non-US based recipient of this honor. He also won Kwiat Prize for Basic Medical Science Subject Area and Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Sciences.
 
He was granted his post graduate board certification from Harvard University, in addition to several other board certifications. His contributions to human genetics have been instrumental in elucidating the physiological and structural roles of hundreds of genes, resulting in the diagnosis of many genetic disorders. His discoveries have significantly advanced the understanding of the intricate relationship between human genes and health.
 
“We are delighted to welcome such a trusted and respected leader to the Lifera Omics Executive Leadership team,” said Dr. Ibrahim Juffali, Chairman of Lifera. “Dr. Fowzan’s deep clinical and scientific expertise will be instrumental in helping Lifera achieve its mission to improve Saudi Arabia’s biopharma resilience and to enable the National Biotech Strategy.”